Search Results

Nielsen BioSciences, Inc. today announced the first patient enrolled in CFW-3A – a Phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of CANDIN ® for the treatment of Verruca vulgaris (common warts) in adolescents and adults.

Vial, a global tech-driven CRO providing next-generation clinical trial management services, has partnered with Nielsen BioSciences, Inc. (Nielsen), a privately-held biopharmaceutical company based in San Diego, CA, to study the safety and efficacy of CANDIN® for the treatment of common warts.

Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, today announced that it has entered into a license agreement with Maruho Co., Ltd. (“Maruho”), granting Maruho exclusive rights to market CANDINⓇ in Japan for the treatment of Verruca vulgaris (common warts).

Octave ® Bioscience, Inc. today announced the publication of a landmark manuscript in the prestigious journal, Nature Communications.

Xenetic Biosciences, Inc. today announced the appointment of James Parslow, the Company’s Chief Financial Officer, as interim Chief Executive Officer, effective May 16, 2024.

Co-Diagnostics, Inc. today announced that last month the Board of Directors appointed Richard Abbott as President of Co-Diagnostics, Inc., concurrent with the Company naming David Nielsen to be its Chief Operations Officer (COO), Christopher Thurston as its Chief Technology Officer (CTO), and Seth Egan as Chief Commercialization Officer (CCO).

Avidity Biosciences, Inc. announced the pricing of an underwritten public offering of 10,550,000 shares of its common stock at a price to the public of $38.00 per share.

Pulse Biosciences, Inc. today announced that it has commenced its previously announced rights offering of up to $60,000,000 of units (the “Units,” and each, a “Unit”) at the Initial Price (as defined below).